The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma

• 作者: Li Liu Shuai Kang Shujie Chen Xue Bai Yang Song
• 来源期刊: 介入医学杂志
• 学科: 医学
• 关键词: HEPATOCELLULAR CARCINOMA Combinational therapy IMMUNOTHERAPY IMMUNE CHECKPOINT
• 年，卷（期）: 2019,（2）
• 页码范围: 47-51
• 页数: 5页
• 分类号: R735.7

摘要

The treatment choices available for hepatocellular carcinoma(HCC)are limited and unsatisfactory.Recent improvements in our understanding of the mechanism involving immune checkpoints,including programmed cell death protein 1(PD1),programmed death-ligand 1(PD-L1),and cytotoxic T-lymphocyte-associated protein 4(CTLA-4),and also progress in the development of medicines make immunotherapy a promising approach to the treatment of numerous cancers,especially HCC.However,around 40%of patients still suffer from a progressive disease when treated with a monotherapy.Several clinical trials applying a combination therapy including immune checkpoint inhibitors have demonstrated the durable antitumor activity of these approaches in HCC patients.These clinical trials were done with the intent of evaluating the safety of these combination therapies,as well as whether they help improve the overall survival of patients.This study reviewed the recent progress in the use of combination therapies including immunotherapy in treating patients with HCC.